Document is current

Article History

Accepted: 1 August 2024

First Online: 8 November 2024

Declarations

:

: VP, SB, and TR report no financial or non-financial conflicts of interest. KM reports being engaged as a consultant and global trial principal investigator for ImaginAb and as a consultant for Werewolf, Xilio, Beigene, Astra-Zeneca, and BMS. Additionally, KM has participated in mock ODAC roles for Beigene, Astra-Zeneca, Merck, and BMS. KM reports being engaged as a consultant and global trial principal investigator for ImaginAb. Additionally, KM has participated in mock ODAC roles for Beigene, Astra-Zeneca, Merck, Daiichi-Sankyo, and BMS. KM is part of the adjuvant trial steering committee and local trial principal investigator for Regeneron and holds local trial principal investigator roles for Agenus and ImmunoCore. PA receives research funding for her institution from companies including Gilead, Agendia, Astra Zeneca, Caris Life Sciences, Seagen, Atossa Therapeutics, Modulation Therapeutics, Biovica International, Loxo Lilly, and Sermonix. PA serves on advisory boards for Epic Sciences, Biovica International, Astra Zeneca, and Hesian Labs, and provides consulting, honoraria, or speakers bureau services for GE Healthcare, AstraZeneca, MJH Lifesciences, Menarini Stemline, Iksuda Therapeutics, Breathe Biomedical, Daichi Sankyo, and Guardant Health. RLM reports the following: Consultant/Advisor: Agendia, Astra Zeneca, Daiichi, Eisai, Genentech, Gilead, Hologic, Lilly, Novartis, Pfizer, Puma, Sanofi, Sermonix, Stemline Research support: Gilead. VS reports grants from Eli Lilly/LOXO Oncology, Blueprint Medicines Corporation, Turning Point Therapeutics, Boston Pharmaceuticals, and Helsinn Pharmaceuticals. He also reports grants and services in an advisory board/consultant position for Eli Lilly/Loxo Oncology. He has received research grants from Roche/Genentech, Bayer, GlaxoSmithKline, Nanocarrier, Vegenics, Celgene, Northwest Biotherapeutics, Berghealth, Incyte, Fujifilm, D3, Pfizer, Multivir, Amgen, Abbvie, Alfa-sigma, Agensys, Boston Biomedical, Idera Pharma, Inhibrx, Exelixis, Blueprint Medicines, Altum, Dragonfly Therapeutics, Takeda, National Comprehensive Cancer Network, NCI-CTEP, the University of Texas MD Anderson Cancer Center, Turning Point Therapeutics, Boston Pharmaceuticals, Novartis, Pharmamar, and Medimmune. He has served on an advisory board and as a consultant for Helsinn, Incyte, QED Pharma, Daiichi-Sankyo, Signant Health, Novartis, Relay Therapeutics, Roche, and Medimmune. He has received travel funds from Pharmamar, Incyte, ASCO, and ESMO, as well as other support from Medscape. MSA has received grants from Seagen and holds consulting roles with several companies, including Bayer, Kiyatec, Insightec, GSK, Xoft, Nuvation, SDP Oncology, Apollomics, Prelude, Janssen, Voyager Therapeutics, Viewray, Caris Lifesciences, Pyramid Biosciences, Varian Medical Systems, Cairn Therapeutics, Anheart Therapeutics, Theraguix, Menarini Ricerche, Sumitomo Pharma Oncology, Autem Therapeutics, GT Medical Technologies, Allovir, and Equillium Bio. He is on the Data Safety Monitoring Committee for VBI Vaccines and serves on the Scientific Advisory Board for Modifi Biosciences and Bugworks. Additionally, MSA is a shareholder in Mimivax, Cytodyn, MedInnovate Advisors LLC, and Trisalus Lifesciences.